San Francisco Bay Area biotech stories.
Monday, September 24, 2012
One-on-One with biotech executive Fran Heller
Fran Heller is a hawk when it comes to finding a drug deal. Now she's passing on her knowledge of the all-important deal that often determines whether a biotech company lives or dies.
On Monday, Heller started her second year of teaching
a six-week continuing studies course
on the ins-and-outs of the drug development world. Heller has assembled or participated in nearly 100 transactions during her career, including her three years as vice president of business development at South San Francisco's
which she left in July 2011
. She also was head of strategic alliances at the Novartis Institute for Biomedical Research, vice president of corporate development and legal affairs at Signature BioScience Inc. and worked at Celera Genomics. I spoke with Heller about her Stanford course, called "New Drug Challenges for Biotech and Pharmaceutical Companies," and the hurdles faced by drug-development companies.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)